Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06967103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

StatusRecruiting
PhasePhase 2
Started2025-09-08
View on ClinicalTrials.gov ↗

Amendment history

2026-01-07
Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05-20→confirmed 2025-09-08
Study sites0→1
2025-05-09
Original filing
The goal of this clinical trial is to learn if QL1706 is effective in early HR+/HER2- breast cancer. It will also learn about the safety of QL1706. The main questions it aims to answer are: Does QL1706 combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- breast cancer? What adverse events do participants have when receiving QL1706? Participants will: Receive QL1706 plus chemotherapy or chemotherapy every 3 weeks for 6 cycles; All patients will receive surgery, and the primary end point is pathological complete response at the time of definitive surgery; After definitive surgery, the participants will receive adjuvant QL1706 every 3 weeks for up to 6 months from the beginning of the treatment.
Trial Details
NCT Number NCT06967103
Lead Sponsor Henan Cancer Hospital
Conditions Breast Cancer, HR+/HER2- Breast Cancer
Enrollment 238 participants
Start Date 2025-09-08
Primary Completion 2027-05-31 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-08